Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
izalontamab brengitecan + osimertinib
- Development stage
- Unknown
- Lead developer
- SystImmune
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (izalontamab Brengitecan), Oral (osimertinib)
01
Overview
izalontamab brengitecan + osimertinib is an investigational combination therapy being evaluated for advanced non-small cell lung cancer (NSCLC) in patients harboring EGFR mutations who have progressed after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy[1][3][4]. - **Izalontamab brengitecan** is a bispecific antibody-drug conjugate (ADC) designed to simultaneously target Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3). Upon binding, it delivers a DNA topoisomerase I inhibitor payload that damages cancer cell DNA and induces cell death[1][3][7]. - **Osimertinib** is a third-generation EGFR tyrosine kinase inhibitor that selectively inhibits both EGFR-sensitizing and T790M resistance mutations. The combination aims to provide a more comprehensive blockade of EGFR signaling with direct inhibition (osimertinib) plus receptor targeting and cytotoxic payload delivery (izalontamab brengitecan), particularly for patients who have developed resistance to prior EGFR-targeted therapy.
- Brand names
- Yizekang + Tagrisso
- Other names
- izalontamab brengitecan + osimertinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on izalontamab brengitecan + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on izalontamab brengitecan + osimertinib.